Does Rallies show 13F holders for ZVRA?

Yes. Rallies tracks hedge fund and 13F ownership data for ZVRA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ZVRA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ZVRA. It does not provide personalized investment advice.

ZVRA (Zevra Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Zevra Therapeutics, Inc. Common Stock (ZVRA) is a publicly traded Healthcare sector company. As of May 21, 2026, ZVRA trades at $10.18 with a market cap of $616.57M and a P/E ratio of 7.30. ZVRA moved +0.20% today. Year to date, ZVRA is +22.78%; over the trailing twelve months it is +18.93%. Its 52-week range spans $6.19 to $13.16. Analyst consensus is strong buy with an average price target of $24.00. Rallies surfaces ZVRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ZVRA stock?

Hedge funds tracked by Rallies that own ZVRA include Panagora Asset. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Zevra Therapeutics, Inc. Common Stock.

ZVRA Key Metrics

Key financial metrics for ZVRA
Metric	Value
Price	$10.18
Market Cap	$616.57M
P/E Ratio	7.30
EPS	$1.40
Dividend Yield	0.00%
52-Week High	$13.16
52-Week Low	$6.19
Volume	40
Avg Volume	0
Revenue (TTM)	$106.47M
Net Income	$83.23M
Gross Margin	0.00%

Top Hedge Funds Holding ZVRA

Panagora Asset holds 67.48K shares of ZVRA, changed +0.00% as of Sep 30, 2025.

Latest ZVRA News

Zevra Q1 Revenue Soars 78% to $36.2M; Net Income Hits $37.9M — May 6, 2026
Zevra Therapeutics Records $106.5M Revenue, MIPLYFFA Sales of $87.4M in 2025 — Mar 12, 2026
Zevra Therapeutics Shares Rise 21.7% on Q4 Beat and GeneDx NPC Testing Pact — Mar 10, 2026
Zevra Posts $106.5M 2025 Revenue and $83.2M Net Income — Mar 9, 2026
Zevra Therapeutics Appoints CFO Justin Renz with 25+ Years Biopharma Finance Experience — Mar 5, 2026

Recent ZVRA Insider Trades

Thompson Rahsaan sold 1.79K (~$20.27K) on May 11, 2026.
McFarlane Neil F. sold 14.63K (~$125.19K) on Feb 9, 2026.
Sangiovanni Timothy J. sold 3.00K (~$27.55K) on Feb 3, 2026.

ZVRA Analyst Consensus

7 analysts cover ZVRA: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.00.

Common questions about ZVRA

Who owns ZVRA stock?: Hedge funds tracked by Rallies that own ZVRA include Panagora Asset. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Zevra Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for ZVRA?: Yes. Rallies tracks hedge fund and 13F ownership data for ZVRA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ZVRA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ZVRA. It does not provide personalized investment advice.